Advertisement
COO vs DXR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and DXR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 0 FA rating(s) are green whileDXR’s FA Score has 0 green FA rating(s).
- COO’s FA Score: 0 green, 5 red.
- DXR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while DXR’s TA Score has 4 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 5 bearish.
- DXR’s TA Score: 4 bullish, 4 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а +4.23% price change this week, while DXR (@Pharmaceuticals: Other) price change was +5.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.53%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +4.24%.
Reported Earning Dates
COO is expected to report earnings on Aug 27, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+0.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| COO | DXR | COO / DXR | |
| Capitalization | 14.6B | 52.6M | 27,757% |
| EBITDA | 1.1B | N/A | - |
| Gain YTD | -20.309 | 37.841 | -54% |
| P/E Ratio | 35.39 | 6.64 | 533% |
| Revenue | 3.99B | 2.13M | 187,142% |
| Total Cash | 116M | N/A | - |
| Total Debt | 2.59B | 730K | 354,110% |
COO | DXR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 94 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | |
SMR RATING 1..100 | 82 | 88 | |
PRICE GROWTH RATING 1..100 | 62 | 40 | |
P/E GROWTH RATING 1..100 | 89 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (78) in the Medical Specialties industry is in the same range as DXR (86). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
COO's Profit vs Risk Rating (98) in the Medical Specialties industry is in the same range as DXR (100). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
COO's SMR Rating (82) in the Medical Specialties industry is in the same range as DXR (88). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
DXR's Price Growth Rating (40) in the Medical Specialties industry is in the same range as COO (62). This means that DXR’s stock grew similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (89) in the Medical Specialties industry is in the same range as DXR (100). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
| COO | DXR | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 69% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 68% |
| Advances ODDS (%) | 4 days ago 62% | 5 days ago 66% |
| Declines ODDS (%) | 2 days ago 59% | 2 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 71% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CQQQ | 49.03 | 0.84 | +1.74% |
| Invesco China Technology ETF | |||
| AVIE | 61.00 | 0.23 | +0.38% |
| Avantis Inflation Focused Equity ETF | |||
| FISR | 25.75 | -0.02 | -0.08% |
| SPDR® SSGA Fixed Inc Sect Rotation ETF | |||
| NMS | 11.38 | -0.01 | -0.09% |
| Nuveen Minnesota Quality Municipal Income Fund | |||
| STHH | 50.77 | -0.56 | -1.10% |
| STMICROELECTRONICS NV ADRHEDGED STHH | |||
DXR and
Correlation & Price change
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -0.09% | ||
| IART - DXR | 33% Poorly correlated | +4.19% | ||
| BWAY - DXR | 27% Poorly correlated | +1.17% | ||
| NOTV - DXR | 24% Poorly correlated | +2.72% | ||
| QIPT - DXR | 23% Poorly correlated | +2.51% | ||
| COO - DXR | 20% Poorly correlated | -0.25% | ||
More | ||||